Sangamo BioSciences to Webcast Analyst Briefing on Thursday, December 6, 2012
RICHMOND, Calif., Nov. 27, 2012 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO), announced today that it will host a live webcast of its upcoming Analyst and Investor Briefing which will be held in New York City at 5:00 pm ET on Thursday, December 6, 2012. During the briefing, members of Sangamo's management team will provide an update on the company's technology platform advancements and pipeline of ZFP Therapeutics® as well as near- and mid-term operating goals.
The presentations may be accessed via a link on the Sangamo BioSciences website in the Investor Relations section http://investor.sangamo.com/index.cfm under Events and Presentations. A replay of the presentations will be archived on the Sangamo website and will be available approximately two hours after the event.
About Sangamo
Sangamo BioSciences, Inc. is focused on research and development of novel DNA-binding proteins for therapeutic gene regulation and genome editing. The Company has ongoing Phase 2 clinical trials to evaluate the safety and efficacy of a novel ZFP Therapeutic® for the treatment of HIV/AIDS. Sangamo's other therapeutic programs are focused on monogenic diseases, including hemophilia, Huntington's disease and hemoglobinopathies such as sickle cell anemia and beta-thalassemia. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs). Engineering of ZFPs that recognize a specific DNA sequence enables the creation of sequence-specific ZFP Nucleases (ZFNs) for gene modification and ZFP transcription factors (ZFP TFs) that can control gene expression and, consequently, cell function. Sangamo has entered into a strategic collaboration with Shire AG to develop therapeutics for hemophilia, Huntington's disease and other monogenic diseases and has established strategic partnerships with companies in non-therapeutic applications of its technology including Dow AgroSciences and Sigma-Aldrich Corporation. For more information about Sangamo, visit the company's website at www.sangamo.com.
ZFP Therapeutic® is a registered trademark of Sangamo BioSciences, Inc.
SOURCE Sangamo BioSciences, Inc.
RELATED LINKS
http://www.sangamo.com
More by this Source
Sangamo BioSciences Presents New Data From In Vivo Protein Replacement Platform For Development Of ZFP Therapeutics® For Monogenic Diseases
May 20, 2013, 07:00 ET
Sangamo BioSciences Presents Clinical Data Demonstrating HIV Reservoir Reduction in HIV-Infected Subjects Treated with ZFP Therapeutic®, SB-728-T
May 15, 2013, 10:00 ET
Sangamo BioSciences Announces Presentation at the Bank of America Merrill Lynch 2013 Health Care Conference
May 09, 2013, 16:05 ET
Featured Video
Journalists and Bloggers
Visit PR Newswire for Journalists for releases, photos, ProfNet experts, and customized feeds just for Media.
View and download archived video content distributed by MultiVu on The Digital Center.
Custom Packages
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.